PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20801430-2 2011 Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-alpha). oleoylethanolamide 172-190 fatty-acid amide hydrolase-like Rattus norvegicus 14-18 23573230-5 2013 Among those tested, the 200 microg/rat dose of URB597 was the only one that elevated the levels of the FAAH non-endocannabinoid and anti-inflammatory substrates, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), and of the endocannabinoid FAAH substrate, 2-arachidonoylglycerol, and fully inhibited thermal and tactile nociception, although in a manner blocked almost uniquely by TRPV1 antagonism. oleoylethanolamide 182-185 fatty-acid amide hydrolase-like Rattus norvegicus 103-107 26642910-8 2017 AEA levels were significantly elevated in all three treatment groups as were palmitoylethanolamide and oleoylethanolamide, which are also substrates for FAAH. oleoylethanolamide 103-121 fatty-acid amide hydrolase-like Rattus norvegicus 153-157 25245162-3 2014 administration of the FAAH inhibitor URB597 increased hippocampal levels of the N-acylethanolamines palmitoylethanolamide and oleoylethanolamide, but not anandamide. oleoylethanolamide 126-144 fatty-acid amide hydrolase-like Rattus norvegicus 22-26 24433863-2 2014 A potent member of this class, (37), was found to inhibit FAAH centrally, elevate the brain levels of three fatty acid ethanolamides [FAAs: anandamide (AEA), oleoyl ethanolamide (OEA) and palmitoyl ethanolamide (PEA)], and was moderately efficacious in a rat model of neuropathic pain. oleoylethanolamide 158-177 fatty-acid amide hydrolase-like Rattus norvegicus 58-62 24433863-2 2014 A potent member of this class, (37), was found to inhibit FAAH centrally, elevate the brain levels of three fatty acid ethanolamides [FAAs: anandamide (AEA), oleoyl ethanolamide (OEA) and palmitoyl ethanolamide (PEA)], and was moderately efficacious in a rat model of neuropathic pain. oleoylethanolamide 179-182 fatty-acid amide hydrolase-like Rattus norvegicus 58-62 22029844-10 2012 The cytoprotective response to OEA was lost during exposure to inhibitors of fatty acid amide hydrolase (FAAH) suggesting that OEA per se is not the cytoprotective species but that release of free oleate is required. oleoylethanolamide 31-34 fatty-acid amide hydrolase-like Rattus norvegicus 77-103 22029844-10 2012 The cytoprotective response to OEA was lost during exposure to inhibitors of fatty acid amide hydrolase (FAAH) suggesting that OEA per se is not the cytoprotective species but that release of free oleate is required. oleoylethanolamide 31-34 fatty-acid amide hydrolase-like Rattus norvegicus 105-109 22029844-10 2012 The cytoprotective response to OEA was lost during exposure to inhibitors of fatty acid amide hydrolase (FAAH) suggesting that OEA per se is not the cytoprotective species but that release of free oleate is required. oleoylethanolamide 127-130 fatty-acid amide hydrolase-like Rattus norvegicus 77-103 22029844-10 2012 The cytoprotective response to OEA was lost during exposure to inhibitors of fatty acid amide hydrolase (FAAH) suggesting that OEA per se is not the cytoprotective species but that release of free oleate is required. oleoylethanolamide 127-130 fatty-acid amide hydrolase-like Rattus norvegicus 105-109 22029844-13 2012 Rather, OEA is internalised and subjected to hydrolysis by FAAH to release free oleate, which then mediates the cytoprotection. oleoylethanolamide 8-11 fatty-acid amide hydrolase-like Rattus norvegicus 59-63 20801430-2 2011 Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-alpha). oleoylethanolamide 192-195 fatty-acid amide hydrolase-like Rattus norvegicus 14-18 21779318-2 2011 The hydrolysis of OEA and PEA is catalyzed by the fatty acid amide hydrolase (FAAH). oleoylethanolamide 18-21 fatty-acid amide hydrolase-like Rattus norvegicus 78-82 21779318-3 2011 A number of FAAH inhibitors that increase the levels of OEA and PEA in the brain have been developed, including URB597. oleoylethanolamide 56-59 fatty-acid amide hydrolase-like Rattus norvegicus 12-16 19403796-1 2009 Inhibitors of fatty acid amide hydrolase (FAAH) increase endogenous levels of anandamide (a cannabinoid CB(1)-receptor ligand) and oleoylethanolamide and palmitoylethanolamide (OEA and PEA, ligands for alpha-type peroxisome proliferator-activated nuclear receptors, PPAR-alpha) when and where they are naturally released in the brain. oleoylethanolamide 131-149 fatty-acid amide hydrolase-like Rattus norvegicus 14-40 20353771-10 2010 Inhibitors of the acylethanolamide-degrading enzyme FAAH can increase levels of all acylethanolamides including annandamide, and some of the pharmacological effects caused by these inhibitors may be explained by increased cerebral levels of OEA and PEA, e.g., suppression of nicotine-induced activation of dopamine neurons. oleoylethanolamide 241-244 fatty-acid amide hydrolase-like Rattus norvegicus 52-56 19403796-1 2009 Inhibitors of fatty acid amide hydrolase (FAAH) increase endogenous levels of anandamide (a cannabinoid CB(1)-receptor ligand) and oleoylethanolamide and palmitoylethanolamide (OEA and PEA, ligands for alpha-type peroxisome proliferator-activated nuclear receptors, PPAR-alpha) when and where they are naturally released in the brain. oleoylethanolamide 131-149 fatty-acid amide hydrolase-like Rattus norvegicus 42-46 19403796-1 2009 Inhibitors of fatty acid amide hydrolase (FAAH) increase endogenous levels of anandamide (a cannabinoid CB(1)-receptor ligand) and oleoylethanolamide and palmitoylethanolamide (OEA and PEA, ligands for alpha-type peroxisome proliferator-activated nuclear receptors, PPAR-alpha) when and where they are naturally released in the brain. oleoylethanolamide 177-180 fatty-acid amide hydrolase-like Rattus norvegicus 14-40 19403796-1 2009 Inhibitors of fatty acid amide hydrolase (FAAH) increase endogenous levels of anandamide (a cannabinoid CB(1)-receptor ligand) and oleoylethanolamide and palmitoylethanolamide (OEA and PEA, ligands for alpha-type peroxisome proliferator-activated nuclear receptors, PPAR-alpha) when and where they are naturally released in the brain. oleoylethanolamide 177-180 fatty-acid amide hydrolase-like Rattus norvegicus 42-46 17336288-2 2007 The hydrolysis of this lipid involves the activity of the fatty acid amide hydrolase (FAAH), which additionally catalyzes the degradation of the satiety factor oleoylethanolamide and the analgesic-inducing lipid palmitoylethanolamide. oleoylethanolamide 160-178 fatty-acid amide hydrolase-like Rattus norvegicus 86-90 17336288-3 2007 It has been demonstrated that the inhibition of the FAAH by URB597 increases levels of anandamide, oleoylethanolamide and palmitoylethanolamide in the brain of rats. oleoylethanolamide 99-117 fatty-acid amide hydrolase-like Rattus norvegicus 52-56 17336288-13 2007 Our results suggest that FAAH activity as well as two molecules that are catalyzed by this enzyme, oleoylethanolamide and palmitoylethanolamide, participate in the regulation of the waking state. oleoylethanolamide 99-117 fatty-acid amide hydrolase-like Rattus norvegicus 25-29 32075117-4 2020 Moreover, it decreased cardiac or plasma levels of anandamide, 2-arachidonoylglycerol and oleoyl ethanolamide in DOCA-salt and inhibited the activity of fatty acid amide hydrolase (FAAH) in both models. oleoylethanolamide 90-109 fatty-acid amide hydrolase-like Rattus norvegicus 181-185 12773040-1 2003 Fatty acid amide hydrolase (FAAH), an intracellular serine hydrolase enzyme, participates in the deactivation of fatty acid ethanolamides such as the endogenous cannabinoid anandamide, the intestinal satiety factor oleoylethanolamide, and the peripheral analgesic and anti-inflammatory factor palmitoylethanolamide. oleoylethanolamide 215-233 fatty-acid amide hydrolase-like Rattus norvegicus 28-32 30251159-6 2018 This effect was strongly correlated with inhibition of brain FAAH activity (r2 = 1.0) and was accompanied by increased brain levels of three FAAH substrates: the endocannabinoid anandamide and the endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). oleoylethanolamide 280-298 fatty-acid amide hydrolase-like Rattus norvegicus 61-65 30251159-6 2018 This effect was strongly correlated with inhibition of brain FAAH activity (r2 = 1.0) and was accompanied by increased brain levels of three FAAH substrates: the endocannabinoid anandamide and the endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). oleoylethanolamide 280-298 fatty-acid amide hydrolase-like Rattus norvegicus 141-145 30251159-6 2018 This effect was strongly correlated with inhibition of brain FAAH activity (r2 = 1.0) and was accompanied by increased brain levels of three FAAH substrates: the endocannabinoid anandamide and the endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). oleoylethanolamide 300-303 fatty-acid amide hydrolase-like Rattus norvegicus 61-65 30251159-6 2018 This effect was strongly correlated with inhibition of brain FAAH activity (r2 = 1.0) and was accompanied by increased brain levels of three FAAH substrates: the endocannabinoid anandamide and the endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonists, oleoylethanolamide (OEA), and palmitoylethanolamide (PEA). oleoylethanolamide 300-303 fatty-acid amide hydrolase-like Rattus norvegicus 141-145